Immune checkpoint inhibitors, such as ipilimumab (monoclonal antibody to CTLA4) and nivolumab (monoclonal antibody to PD-1), have demonstrated survival benefits in multiple tumor types, including melanoma, non-small cell lung cancer, and renal cell carcinoma. This evidence concerns the gene CTLA4 and neoplasm.